Clinical trials
Systemic Sclerosis clinical trials
Below are recruiting systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06058091RecruitingPhase 1/Phase 2
Cell injection therapy for systemic sclerosis
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Nanjing, JiangsuAges 18–65 - NCT07836361Recruiting
A study following people with systemic sclerosis over time
This study follows people with systemic sclerosis (a condition that causes hardening and tightening of the skin and can affect organs) to learn more about the disease over time. By joining, you help researchers understand it better, and you may get more careful monitoring.
BeijingAges Up to 100 years - NCT07842133Recruiting
Relaxation exercises for fatigue and breathing in scleroderma
This study tests whether progressive muscle relaxation exercises can help reduce fatigue and shortness of breath while improving lung function in people with scleroderma. Participants will learn and practice these exercises as part of the study.
Gaziantep, ŞehitkamilAges 18–65 - NCT06462768Recruiting
Study of immune cell activity in systemic sclerosis
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
ReimsAges 18 years+ - NCT06414135RecruitingPhase 1
CAR-T therapy for people with diffuse scleroderma
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
ShanghaiAges 18–65 - NCT07641634RecruitingPhase 1/Phase 2
Testing PRO-203 for active systemic sclerosis
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
Melbourne, VictoriaAges 18–65 - NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Birmingham, AlabamaAges 18 years+ - NCT07360808Recruiting
Fat Cell Therapy for Hand Problems in Scleroderma
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
Guangzhou, GuangdongAges 18–70 - NCT07292961Recruiting
Exercise program for people with scleroderma
This study tests if a special exercise program based on your body and mind can help people with scleroderma feel better. It is for both children (ages 7-18) and adults.
Ankara, AltındağAges 7 years+ - NCT06865118Recruiting
Home management of heart issues in scleroderma
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
OsloAges 18 years+ - NCT07236970Recruiting
AI screening for pulmonary hypertension in scleroderma
This study uses artificial intelligence to find better ways to screen for pulmonary arterial hypertension (a type of high blood pressure in the lungs) in people with systemic sclerosis (scleroderma). The goal is to catch the condition earlier so treatment can start sooner.
Granada, AndalusiaAges 18–80 - NCT05016804RecruitingPhase 1
Umbilical cord stem cell infusion trial for systemic sclerosis
This early safety study tests whether an intravenous (through a vein) stem cell product made from donated umbilical cord cells is safe for people with systemic sclerosis. If you join, the goal is to see how your body tolerates the treatment and monitor for side effects.
St John'sAges Any age - NCT07047690RecruitingPhase 2
Nemolizumab for adults with scleroderma
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Ann Arbor, MichiganAges 18 years+ - NCT05989763Recruiting
Constipation study for people with systemic sclerosis
This study looks at why people with systemic sclerosis (a disease that can affect connective tissues) develop constipation. It will use special tests to measure how well the colon moves waste, and it may help doctors find better treatments.
Houston, TexasAges 18 years+ - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06658483Enrolling by invitation
Hand Scleroderma Experience Survey for People With Systemic Sclerosis
This study is testing a new scale to measure what it's like to live with hand problems caused by systemic sclerosis (scleroderma). By answering questions about your daily hand function, you can help doctors better understand your experience and improve care.
Malatya, MalatyaAges 18 years+ - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Phoenix, ArizonaAges 18 years+ - NCT03211793RecruitingPhase 1/Phase 2
Cell treatment for painful hand sores in systemic sclerosis
This trial tests a cell-based treatment (mesenchymal stromal cells) to help heal painful finger/toe ulcers in people with systemic sclerosis. It is for ulcers that did not improve after a specific IV medicine called prostacyclins.
UtrechtAges 18 years+ - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT04789850RecruitingPhase 2
Itacitinib for adults with diffuse systemic sclerosis
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
AmiensAges 18 years+ - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT05273138Recruiting
Study of skin immune and support cells in systemic sclerosis
This study looks at skin cells and immune cells in people with systemic sclerosis to better understand what drives the disease. Your participation may help researchers learn how the immune system and skin support cells change over time.
LilleAges 18 years+ - NCT05177380Recruiting
Personalized facial rehabilitation program for systemic sclerosis
This trial tests a personalized rehabilitation program aimed at improving facial symptoms in people with systemic sclerosis. It may help you with facial involvement while researchers measure how well the program works and is tolerated.
Strasbourg, Bas-RhinAges 18 years+
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Systemic Sclerosis trials by city
Studies with a site in or near these metro areas.
Systemic Sclerosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for systemic sclerosis?
- Yes. Clin2 currently lists 165 recruiting systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.